Loading
Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.
Ajai Chari was principal investigator and first author of MonumenTAL-1, the trial that established the GPRC5DxCD3 bispecific talquetamab in relapsed myeloma and validated a target beyond BCMA. He has led studies of subcutaneous daratumumab, selinexor and real-world outcomes in myeloma and directs the myeloma programme at UCSF after many years at Mount Sinai.
Shares CD38, CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tags myeloma, bispecific.
Shares MonumenTAL-1, GPRC5D, Multiple myeloma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
Shares Bispecific antibodies, T-cell engagers (bispecific), Multiple myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.